But in any case, since gene silencing drugs are under development to attenuate both HTT expression for HD and to attenuate MAPT expression for FTD-MAPT (Mullard, 2019), it is conceivable that the combined therapy in HD patients might be more effective than HTT silencing alone. This evidence concerns the gene MAPT and Huntington disease.